Jubilant Ingrevia is going ahead with its expansion plan. The company’s capex execution track record highlights its dedication to expanding and diversifying its business mix to enhance profitability. The company is focussed on value-added specialty chemical products.

“To achieve our goals, we have invested Rs. 1,745 crore in last 3 years out of the announced Capex plans of Rs. 2,000 crore in FY’22. Looking ahead to FY’26 and beyond, we plan to invest in high-growth projects such as multipurpose plants for fine chemicals, Diketene Derivatives, new CDMO projects and Human Nutrition & Health,” the company said in a statement.

Jubilant Ingrevia expects sustained growth and improved business performance, driven by advancements in Specialty Chemicals and Nutrition & Health Solutions, along with efficient cost management. “We remain committed to our Pinnacle 345 vision and are on track to achieve our envisaged growth plans,” the statement added.